A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN TREATMENT CROSSOVER BIOAVAILABILITY STUDY (PART 2) OF LT-NS001 AND NAPROXEN ADMINISTERED IN HEALTHY SUBJECTS

Published: 16-11-2007 Last updated: 10-05-2024

_

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeOther conditionStudy typeInterventional

Summary

ID

NL-OMON31529

Source

ToetsingOnline

Brief title

LT-NS001 escalating multiple dose and bioavailability study

Condition

Other condition

Synonym

Chronic pain

Health condition

Chronische pijn zoals bij Rheumatische arthritis

Research involving Human Sponsors and support

Primary sponsor: Logical Therapeutics, Inc

Source(s) of monetary or material Support: Logical Therapeutics Inc

Intervention

Keyword: Bioavailability, LT-NS001, Single-blind

Outcome measures

Primary outcome

_

Secondary outcome

-

Study description

Background summary

-

Study objective

-

Study design

_

Intervention

_

Study burden and risks

_

2 - A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN ... 6-05-2025

Contacts

Public

Logical Therapeutics, Inc

255 Bear Hill Rd, 4th Floor Waltham, MA 02451 USA

Scientific

Logical Therapeutics, Inc

255 Bear Hill Rd, 4th Floor Waltham, MA 02451 USA

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Healthy subjects
Male, 18-70, inclusive (Part 1)
Male/Female, 45-70, inclusive(Part 2), famales must be post menopausal

Exclusion criteria

Pathology for example Hepatitis B, Cancer or HIV/AIDS.

If you have participated in any other drug investigation within 90 days preceding the start of this study or if you have donated blood within 60 days preceding start of this study or loss of blood of similar volume.

Study design

Design

Study type: Interventional

Intervention model: Crossover

Allocation: Randomized controlled trial

Masking: Single blinded (masking used)

Control: Placebo

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 21-11-2008

Enrollment: 36

Type: Actual

Medical products/devices used

Product type: Medicine

Brand name: nvt

Generic name: LT-NS001

Ethics review

Approved WMO

Date: 16-11-2007

Application type: First submission

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Approved WMO

Date: 21-11-2007

Application type: First submission

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Approved WMO

Date: 28-02-2008
Application type: Amendment

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Approved WMO

Date: 06-03-2008

Application type: Amendment

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Approved WMO

Date: 15-04-2008
Application type: Amendment

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

EudraCT EUCTR2007-006163-71-NL

CCMO NL20480.056.07